R&D Towards better quality of life, GNT Pharma

Clinical Research

CRISDESALAZINEPhase 1b clinical study

  • Phase 1b clinical study to assess safety, tolerability, and pharmacokinetics by administering single and multiple ascending doses of crisdesalazine to healthy adult volunteers (aged 19 to 45 years) and healthy elderly volunteers (aged 65 to 85 years).
  • Participating Clinical Center: Seoul National University Bundang Hospital
Total No. of
Enrolled Patients
Progress RateAs of December 1, 2022
40 Pts. 99%
Target No. of Patients 40 Pts.